|
|
|
| Effect of Curcumin on Lung Injury in Mice with ARDS via Regulation of the MAPK/NF-κB Signaling Pathway |
| HU Pan, ZHANG Zhuo |
| Hubei Hospital of Traditional Chinese Medicine, Hubei Wuhan 430001, China |
|
|
|
|
Abstract Objective: To investigate the protective effects of curcumin on acute respiratory distress syndrome (ARDS) in mice by regulating the MAPK/NF-κB signaling pathway. Methods: BALB/C mice were randomly divided into five groups: control group, model group, curcumin group (200mg/kg), anisomycin group (MAPK activator, 20mg/kg), and curcumin (200mg/kg) + anisomycin (20mg/kg) group, with 12 mice per group. ARDS models were established in the model and drug intervention groups via intratracheal instillation of lipopolysaccharide (LPS), while the control group received an equal volume of normal saline. After 3 days of intervention, the following were measured: lung function indices-forced vital capacity (FVC), peak expiratory flow (PEF), and oxygenation index (OI); inflammatory cell count in bronchoalveolar lavage fluid (BALF); histopathological changes and lung injury scores in lung tissues via HE staining; levels of TNF-α, IL-1β, IL-10, and IL-13 in BALF and serum using ELISA; and MAPK/NF-κB pathway protein expression in lung tissues via Western blotting. Results: Compared with the control group, the model group showed significantly increased inflammatory cell count, lung injury score, TNF-α and IL-1β levels, and p-p38 MAPK/p38 MAPK and p-NF-κB p65/NF-κB p65 ratios (P<0.05), while FVC, PEF, OI, IL-10, and IL-13 levels were significantly decreased (P<0.05). Compared with the model group, the curcumin group had reduced inflammatory cell count, lung injury score, TNF-α and IL-1β levels, and p-p38 MAPK/p38 MAPK and p-NF-κB p65/NF-κB p65 ratios (P<0.05), along with increased FVC, PEF, OI, IL-10, and IL-13 levels (P<0.05). The anisomycin group, compared to the model group, exhibited further increases in inflammatory markers and reductions in lung function indices. Co-administration of curcumin and anisomycin negated the protective effects observed in the curcumin group alone. Conclusion: Curcumin inhibits the activation of the MAPK/NF-κB signaling pathway, reducing inflammation, mitigating lung tissue damage, and improving lung function in ARDS mice, thereby exerting a significant protective effect on the lungs.
|
|
|
|
|
|
[1] Saki N,Javan M,Moghimian-boroujeni B,et al.Interesting effects of interleukins and immune cells on acute respiratory distress syndrome[J].Clin Exp Med,2023,23(7):2979-2996.
[2] Lv X,Zheng L,Zhang T,et al.CLCA1 exacerbates lung inflammation via p38 MAPK pathway in acute respiratory distress syndrome[J].Exp Lung Res,2024,50(1):85-95.
[3] Chen L,Gong P,Su Y,et al.Angiotensin Ⅱ type 2 receptor agonist attenuates LPS-induced acute lung injury through modulating THP-1-derived macrophage reprogramming[J].Naunyn Schmiedebergs Arch Pharmacol,2024,397(1):99-108.
[4] Thimmulappa R K,Mudnakudu-nagaraju K K,Shivamallu C,et al.Antiviral and immunomodulatory activity of curcumin: a case for prophylactic therapy for COVID-19[J].Heliyon,2021,7(2):e06350-e06361.
[5] Suresh MV,Francis S,Aktay S,et al.Therapeutic potential of curcumin in ARDS and COVID-19[J].Clin Exp Pharmacol Physiol,2023,50(4):267-276.
[6] Lee D Y,Lee S J,Chandrasekaran P,et al.Dietary curcumin attenuates hepatic cellular senescence by suppressing the MAPK/NF-κB signaling pathway in aged mice[J].Antioxidants (Basel),2023,12(6):1165-1178.
[7] Yang P,Sjoding M W.Acute respiratory distress syndrome: definition,diagnosis,and routine management[J].Crit Care Clin,2024,40(2):309-327.
[8] Chai Y S,Chen Y Q,Lin S H,et al.Curcumin regulates the differentiation of naive CD4+T cells and activates IL-10 immune modulation against acute lung injury in mice[J].Biomed Pharmacother,2020,125(8):109946-109956.
[9] Zhou B,Wang L,Yang S,et al.Diosmetin alleviates benzo [a] pyrene-exacerbated H1N1 influenza virus-induced acute lung injury and dysregulation of inflammation through modulation of the PPAR-γ-NF-κB/P38 MAPK signaling axis[J].Food Funct,2023,14(7):3357-3378. |
|
|
|
2024, Vol. 30 
